Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 2, 2017

BeiGene commences Phase I trial of BGB-A317 in China to treat solid tumours

Clinical-stage biopharmaceutical company BeiGene has commenced its Phase I clinical trial of BGB-A317 in China to treat advanced solid tumours.

Clinical-stage biopharmaceutical company BeiGene has commenced its Phase I clinical trial of BGB-A317 in China to treat advanced solid tumours.

BGB-A317 is a humanised monoclonal antibody belonging to a class of immuno-oncology agents known as immune checkpoint inhibitors.

It specifically fuses with cell surface receptor PD-1, which is considered to play an important role in downregulating the immune system by inhibiting activation of T-cells.

Unlike the currently approved PD-1 antibodies, BGB-A317 can bind with Fc gamma receptor I specifically engineered out.

The Phase I, open-label, multi-centre study of BGB-A317 has been designed to determine the safety, tolerability, preliminary anti-tumour activity and pharmacokinetics profile of BGB-A317 while treating patients with advanced solid tumours in China.

"We are committed to developing BGB-A317 for patients in China, where this exciting class of immuno-oncology agents is still not approved."

Beigene founder and CEO John Oyler said: “We are pleased to report that BGB-A317 is now in Phase I clinical evaluation in mainland China.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“To date, all four of our clinical-stage molecules are active in the clinic in China. We are enthusiastic about the agent’s therapeutic potential, with promising data from an ongoing Phase I study of BGB-A317 in Australia, New Zealand, the US, and Taiwan recently reported at the 2016 Society for Immunotherapy of Cancer Annual Meeting.

“We are committed to developing BGB-A317 for patients in China, where this exciting class of immuno-oncology agents is still not approved.”

The trial will be headed by Professor Yilong Wu from Guangdong General Hospital, while Professor Lin Shen and Professor Jun Guo from Beijing Cancer Hospital will serve as the co-lead investigators.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU